Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12122749 | 0.86 | HRH4 (0.42) | HRH4ADORA2ATLR8 | |
| SCHEMBL1318209 | 0.84 | CYP11B2 (0.47) | CYP11B2CYP11B1 | |
| SCHEMBL1317062 | 0.82 | SMN1; SMN2 (0.55) | CYP11B2CYP11B1HRH4TLR8 | |
| SCHEMBL1317568 | 0.81 | HRH4 (0.52) | CYP11B2CYP11B1HRH4ADORA2ATLR8 | |
| SCHEMBL1319160 | 0.79 | AURKA (0.54) | CYP11B2CYP11B1HRH4 | |
| SCHEMBL2505744 | 0.78 | ADORA1 (0.42) | CYP11B2CYP11B1ADORA2A | |
| SCHEMBL1316983 | 0.77 | AURKA (0.53) | CYP11B2CYP11B1HRH4TLR8 | |
| SCHEMBL1319064 | 0.77 | CYP11B2 (0.44) | CYP11B2CYP11B1HRH4ADORA2A | |
| SCHEMBL1317276 | 0.77 | CYP11B2 (0.68) | CYP11B2CYP11B1ADORA2A | |
| SCHEMBL1317083 | 0.75 | AURKA (0.53) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | CYP11B2 837/4885CYP11B1 634/4885HRH4 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.